Enliven Therapeutics (NASDAQ:ELVN) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Enliven Therapeutics (NASDAQ:ELVN) from a hold rating to a sell rating in a research report released on Saturday morning.

Several other equities research analysts have also recently commented on the stock. The Goldman Sachs Group lifted their price target on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. HC Wainwright increased their price objective on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Friday, July 17th. Guggenheim lowered their target price on shares of Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Thursday. Finally, Stifel Nicolaus lifted their target price on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $72.67.

Enliven Therapeutics Stock Down 1.7%

Shares of ELVN opened at $59.42 on Friday. The stock’s fifty day simple moving average is $49.06 and its 200-day simple moving average is $40.00. The firm has a market capitalization of $4.35 billion, a PE ratio of -35.58 and a beta of 0.27. Enliven Therapeutics has a 12-month low of $14.78 and a 12-month high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Analysts anticipate that Enliven Therapeutics will post -1.67 EPS for the current year.

Insider Transactions at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, July 17th. The shares were sold at an average price of $52.64, for a total transaction of $316,787.52. Following the transaction, the chief financial officer owned 46,054 shares of the company’s stock, valued at $2,424,282.56. This trade represents a 11.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total transaction of $9,561,046.95. Following the transaction, the director owned 87,373 shares of the company’s stock, valued at approximately $5,260,728.33. This represents a 64.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 190,831 shares of company stock worth $10,991,723. 3.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds have recently bought and sold shares of ELVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Enliven Therapeutics by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock valued at $428,000 after buying an additional 1,693 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Enliven Therapeutics by 61.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock valued at $4,167,000 after buying an additional 80,506 shares in the last quarter. Jane Street Group LLC acquired a new stake in Enliven Therapeutics during the 1st quarter worth $578,000. Legal & General Group Plc raised its stake in Enliven Therapeutics by 52.2% during the 2nd quarter. Legal & General Group Plc now owns 32,225 shares of the company’s stock worth $646,000 after buying an additional 11,058 shares during the period. Finally, Quantbot Technologies LP lifted its holdings in Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after acquiring an additional 1,434 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.